Updates in Renal Cell Carcinoma From ESMO 2022

Eric Jonasch, MD


September 30, 2022

Dr Eric Jonasch, from the University of Texas MD Anderson Cancer Center in Houston, discusses the most notable renal cell carcinoma (RCC) data presented at the 2022 European Society for Medical Oncology Congress.

He begins with COSMIC-313, which added cabozantinib to nivolumab plus ipilimumab in intermediate- and poor-risk advanced RCC. The triplet achieved significant improvements in progression-free survival over the standard of care, nivolumab plus ipilimumab.

Dr Jonasch then turns to CheckMate 914, INmotion010, and PROSPER, which investigated the effect of neo/adjuvant immunotherapy after resection. None of the trials were able to replicate the recent positive results with pembrolizumab, raising questions over the future of immunotherapy in this indication.

He next looks at results seen in cohorts 1 and 2 from the LITESPARK-003 study. They showed that belzutifan plus cabozantinib has promising tumor activity in both treated and untreated advanced RCC.

Dr Jonasch then discusses the negative PIVOT-09 trial of bempegaldesleukin plus nivolumab, before ending with KEYNOTE-B61. This phase 2 trial suggests that pembrolizumab plus lenvatinib could be a promising combination in non–clear cell RCC.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.